ROS1 and non-small cell lung carcinoma: Crizotinib inhibits the ALK tyrosine kinase by binding to its ATP-binding pocket, and the introduction of this drug substantially improved prospects in both EML4-ALK positive (31,65) and ROS1 fusion positive NSCLC patients (70,71).